Skip to main content
NMRA logo

NMRA · Neumora Therapeutics, Inc. · Investor Relations

Track NMRA — free
$0.33 -0.01 (-3.78%) At close · Nov 20 Play latest call Q4 2025 earnings call transcript
Market Cap
$63.01M
Shares
188.69M
Volume · Nov 20 1.06M Avg daily vol (3M) 1.67M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-16 Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

IND application for NMRA-215 (NLRP3 inhibitor) submitted to the U.S. Food and Drug Administration Dose-proportional increase in exposure observed in multiple ascending dose (MAD) expansion cohort with NMRA-511 (V1aR antagonist), suggesting potential to build on the efficacy profile demonstrated in

2026-08-14 Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026 Progressing NMRA-511 in Alzheimer’s disease (AD) agitation and NMRA-898 in schizophrenia with clinical data expected in fourth quarter of 2026 and second

2026-07-27 Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026

Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026 WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs

2026-06-15 Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer’s disease agitation, NMRA-898 in schizophrenia and NMRA-215 in cardiometabolic disease Aligning organization

2026-05-12 Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced

2026-05-07 Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer’s disease agitation and NMRA-898 in schizophrenia with clinical data expected for each program in the second half of 2026

2026-04-06 Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference

WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today

2026-03-30 Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies KOASTAL-2 and -3 fully enrolled in the first quarter of 2026; on track for topline readout in the second quarter of 2026 NMRA-898 selected as lead program in

2026-03-16 Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026

WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced

2026-02-04 Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced

2026-01-05 Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones

Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced

Past events

Date Event Type
2026-05-27 Annual Meeting Webcast
2026-05-19 2026 RBC Capital Markets Global Healthcare Conference Conference
2026-04-13 25th Annual Needham Virtual Healthcare Conference Conference
2026-03-30 Earnings conference call (announced in 8-K) Earnings call
2026-02-11 Guggenheim Emerging Outlook: Biotech Summit 2026 Webcast
2026-01-05 Neumora NMRA-511 Update Conference Call Conference
2025-11-12 Stifel 2025 Healthcare Conference Conference
2025-11-10 Guggenheim Second Annual Healthcare Innovation Conference Conference
2025-10-27 Neumora Therapeutics R&D Day Webcast
2025-09-09 H.C. Wainwright 27th Annual Global Investment Conference Conference
2025-08-06 Neumora Second Quarter 2025 Earnings Earnings call
2025-05-28 Annual Meeting Webcast
2025-05-12 Neumora First Quarter 2025 Earnings Conference Call Earnings call
2025-03-03 Neumora Fourth Quarter 2024 Earnings Conference Call Earnings call
2025-01-14 2025 J.P. Morgan Healthcare Conference Conference
2024-11-18 Stifel 2024 Healthcare Conference Conference
2024-11-13 Guggenheim Inaugural Healthcare Innovation Conference Conference
2024-11-12 Neumora Third Quarter 2024 Earnings Conference Call Earnings call
2024-09-12 Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders Webcast
2024-05-15 2024 RBC Capital Markets Global Healthcare Conference Conference
2024-05-14 BofA Securities Healthcare Conference 2024 Conference
2024-03-20 Stifel 2024 Virtual CNS Days Webcast
2024-01-08 42nd Annual J.P. Morgan Healthcare Conference Conference
2023-11-15 Stifel Healthcare Conference Conference
2023-11-06 5th Annual Inflammation, Neurology, & Immunology (INI) Conference Conference

Source: https://ir.neumoratx.com/

Key facts CIK 1885522 CUSIP 640979100 13F (30d) 143 filings 117 filers Visit website Investor relations